Cytokinetics to Announce Second Quarter Results on July 31, 2012
July 24 2012 - 4:00PM
Marketwired
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it
is scheduled to report second quarter results on Tuesday, July 31,
2012 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics' senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and
the company's outlook for the future.
The conference call will be simultaneously webcast and can be
accessed in the Investor Relations section of Cytokinetics' website
at www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 21517396.
An archived replay of the webcast will be available via
Cytokinetics' website until August 7, 2012. The replay will also be
available via telephone by dialing (855) 859-2056 (United States
and Canada) or (404) 537-3406 (international) and typing in the
passcode 21517396 from July 31, 2012 at 5:30 PM Eastern Time until
August 7, 2012.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company
focused on the discovery and development of novel small molecule
therapeutics that modulate muscle function for the potential
treatment of serious diseases and medical conditions. Cytokinetics'
lead drug candidate from its cardiac muscle contractility program,
omecamtiv mecarbil, is in Phase II clinical development for the
potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize
omecamtiv mecarbil and related compounds, subject to Cytokinetics'
specified development and commercialization participation rights.
Cytokinetics is independently developing CK-2017357, a skeletal
muscle activator, as a potential treatment for diseases and
conditions associated with aging, muscle wasting or neuromuscular
dysfunction. CK-2017357 is currently the subject of a Phase II
clinical trials program and has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of
amyotrophic lateral sclerosis, a debilitating disease of
neuromuscular impairment in which treatment with CK-2017357
produced potentially clinically relevant pharmacodynamic effects in
Phase II trials. Cytokinetics is also conducting research on
compounds that inhibit smooth muscle contractility and which may be
useful as potential treatments for diseases and conditions
associated with excessive smooth muscle contraction, such as
bronchoconstriction associated with asthma and chronic obstructive
pulmonary disease. All of these drug candidates and potential drug
candidates have arisen from Cytokinetics' research activities and
are directed towards the cytoskeleton. The cytoskeleton is a
complex biological infrastructure that plays a fundamental role
within every human cell. Additional information about Cytokinetics
can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"). Cytokinetics disclaims any intent or obligation to
update these forward-looking statements, and claims the protection
of the Act's safe harbor for forward-looking statements. Examples
of such statements include, but are not limited to, statements
relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to,
potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics'
drug candidates and potential drug candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
Cytokinetics, Incorporated: Jodi L. Goldstein Manager, Corporate
Communications and Marketing (650) 624-3000
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2024 to Jun 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Jun 2023 to Jun 2024